Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Two androgen receptor inhibitors improved survival by 33% in men with metastatic prostate cancer that responds to hormone therapy.
The combination of chemoimmunotherapy with a targeted drug represents a step toward a new standard of care for people with CLL.
Trying to mimic the “Berlin Patient” cure, researchers edited the CCR5 gene in the immune stem cells of a man with leukemia and HIV.
The International Association for the Study of Lung Cancer made the declaration at the outset of a major cancer meeting in Barcelona.
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
Selpercatinib shrank tumors in 68% of patients previously treated with chemotherapy.
A related study finds patient and provider perceptions about barriers to trial participation are not in sync.
Half of study participants treated with AMG 510 saw their tumors shrink, and only one experienced disease progression.
Task force says some women can benefit from risk-reducing drugs like tamoxifen, but women at average risk should not take them.
The research focuses on natural killer cells, which recognize and attack cells affected by cancer, and genes that help target invaders.
Though small, the increased risk prompted researchers to urge more cautious prescribing.
Thousands of people around the world have already received the promising new therapy.
Study finds early dose reduction of treatment negatively impacts survival rates for women with intermediate- or high-risk breast cancer.
A large analysis finds hormone replacement therapy increases the risk about twice as much as previously thought.
FDA says studies of new breast cancer treatments should allow enrollment of men as well as women.
Wider screening would prevent liver cirrhosis, liver cancer and the need for liver transplants.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.